Breaking

Alphabet beats earnings expectations, raises spending forecast
Uber will let women drivers and riders request to avoid being paired with men
UnitedHealth says it faces DOJ investigation over Medicare billing practices
Homeless people can be removed from streets by cities, states in new Trump executive order
US pulls team from ceasefire talks in Qatar after Israel does the same, claiming Hamas is acting in bad faith
US and Israel urgently need to replenish weapons stockpiles after 12-day war, defense analysts warn
Ron Klain dodges reporters after marathon grilling in Biden cover-up probe
GREGG JARRETT: Newly declassified documents destroy Russian collusion hoax

Politics
Business
World
Investing
Search for:

Investing

Acceleration of RAD204 Phase 1 dose escalation trial

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced Acceleration of RAD204 Phase 1 dose escalation trial

Download the PDF here.

This post appeared first on investingnews.com

0

Related Posts

Glencore to Close Last Australian Copper Mines, Smelter’s Fate Uncertain

xU3O8 Token Launches on Major Global Trading Venues: KuCoin, MEXC and Gate.com

Newmont Uses Drones, Remote Equipment to Reach Trapped Miners in Red Chris Mine

Fill Out & Get More Relevant News

Your name

Your email

Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.
Categories
- Business (1,757)
- Investing (5,539)
- Politics (8,572)
- Uncategorized (2)
- World (6,632)

Disclaimer: upmarketnews.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Latest
- Privacy Policy
- Terms & Conditions

Copyright © 2025 upmarketnews.com | All Rights Reserved

Top

Politics
Business
World
Investing

Type above and press Enter to search. Press Esc to cancel.